...
首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.
【24h】

Changes in hemoglobin level distribution in US dialysis patients from June 2006 to November 2008.

机译:2006年6月至2008年11月,美国透析患者的血红蛋白水平分布发生了变化。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) have had a positive effect on anemia treatment in dialysis patients. However, several events in recent years, including new clinical study results, ESA product label revisions, and coverage and reimbursement policy changes, have had an impact on ESA dosing patterns and consequently on hemoglobin (Hb) distribution characteristics in this patient population. STUDY DESIGN: Retrospective observational study using patient-level data from approximately 87% of dialysis centers in the United States. SETTING & PARTICIPANTS: Dialysis patients who were receiving outpatient care at dialysis facilities during June 2006-November 2008 were included in this study. PREDICTOR: Recent events affecting ESA treatment practice patterns in US dialysis patients. OUTCOMES & MEASUREMENTS: Hb level distribution. RESULTS: Mean Hb level decreased by 0.37 g/dL during the indicated period. Additionally, standard deviation (SD) of the Hb level distribution decreased by 0.14 g/dL and skewness increased by -0.10. Hb measurements in specific ranges changed as follows: >12 g/dL, decreased by 11.3 percentage points;10-12 g/dL, increased by 9.4 percentage points; and <10 g/dL, increased by 1.9 percentage points. The percentage of patients with Hb level >13 g/dL for > or =3 months decreased by 2.9 percentage points. LIMITATIONS: Potential bias in dialysis center selection and lack of information for patient characteristics. CONCLUSIONS: Recent events affecting ESA use in dialysis patients have had the desired effect of increasing the proportion of Hb measurements within the US Food and Drug Administration recommended target range of 10-12 g/dL and decreasing the proportion of Hb measurements >12 g/dL. However, the proportion of Hb measurements <10 g/dL also has increased. Benefits of a decrease in Hb measurements in the >12 g/dL range need to be considered, together with risks of having low Hb levels.
机译:背景:促红细胞生成素(ESA)对透析患者的贫血治疗具有积极作用。但是,近年来发生了几起事件,包括新的临床研究结果,ESA产品标签的修订以及承保范围和报销政策的变化,均对ESA给药方式产生了影响,并因此影响了该患者人群中血红蛋白(Hb)的分布特征。研究设计:回顾性观察研究,使用来自美国约87%透析中心的患者水平数据。地点和参与者:2006年6月至2008年11月期间在透析设施接受门诊护理的透析患者包括在本研究中。预测:影响美国透析患者ESA治疗实践模式的近期事件。结果与测量:血红蛋白水平分布。结果:在所示期间,平均Hb水平降低了0.37 g / dL。此外,Hb水平分布的标准偏差(SD)降低了0.14 g / dL,偏度增加了-0.10。在特定范围内的血红蛋白测量值变化如下:> 12 g / dL,降低了11.3个百分点; 10-12 g / dL,增加了9.4个百分点;和<10 g / dL,增加了1.9个百分点。 Hb水平> 13 g / dL≥3个月或= 3个月的患者百分比降低了2.9个百分点。局限性:透析中心选择的潜在偏见以及患者特征的缺乏信息。结论:最近影响透析患者使用ESA的事件在美国食品和药物管理局建议的10-12 g / dL的目标范围内,具有增加Hb检测比例和降低Hb检测比例> 12 g / d的预期效果。 dL。但是,Hb测量值<10 g / dL的比例也有所增加。需要考虑将血红蛋白测量值降低到> 12 g / dL范围内的好处,以及血红蛋白水平低的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号